Home › Research › Treatments
Clonal expansion of cytotoxic CD8+ T cells in lecanemab-associated ARIA
Johnson LA, Saito K, Pallerla AV, Funnell JL, Ezzo AR, Song CL, Harrison DA, Norton NJ et al.. medRxiv, 2025-09-21
Topic: Brain proteins, microglia and lab models
Plain-language summary
Amyloid-related imaging abnormalities (ARIA) remain the principal safety concern limiting adoption of anti-amyloid therapies such as lecanemab, yet their underlying biology is poorly defined. To address this, we performed deep multi-omic profiling of peripheral blood mononuclear cells from three Alzheimer’s disease (AD) patients who developed ARIA and three matched controls. Single-cell RNA sequencing, CITE-seq, V(D)J clonotyping, and metabolomic/lipidomic profiling revealed a coordinated reprogramming of the CD8 + compartment in ARIA+ patients. CD8 + TEM and TEMRA subsets were numerically expanded, transcriptionally enriched for cytotoxic and migratory programs, and exhibited increased clonal expansion. Transcription factor inference and metabolomics converged on a glycolytic bias, supporting short-lived effector activity. Ligand–receptor modeling identified ARIA-associated signaling from CD14 + and CD16 + monocytes that augmented antigen presentation, adhesion, and chemokine axes directed toward effector CD8s. Finaly, integration with an external cerebrovascular atlas confirmed that ARIA-associated TEM/TEMRAs are transcriptionally “addressed” for vascular engagement. Together, these findings establish a peripheral immune–vascular axis linking immunometabolic reprogramming, clonal cytotoxic CD8 + expansion, and altered monocyte signaling to ARIA, with implications for biomarker development and risk mitigation during anti-amyloid therapy. Significance Anti-amyloid therapies improve Alzheimer’s disease outcomes but are constrained by ARIA, a serious immune–vascular complication with unclear etiology. By integrating single-cell, clonotype, and metabolomic profiling, we show that ARIA is associated with glycolysis-driven expansion of cytotoxic CD8 TEM/TEMRA subsets that engage monocyte and endothelial signaling axes. These findings identify a peripheral immune program that may inform biomarker development and therapeutic strategies to mitigate ARIA risk.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Johnson, L. A., Saito, K., Pallerla, A. V., Funnell, J. L., Ezzo, A. R., Song, C. L., et al. (2025). Clonal expansion of cytotoxic CD8+ T cells in lecanemab-associated ARIA. medRxiv. https://doi.org/10.1101/2025.09.17.25335728
Vancouver
Johnson LA, Saito K, Pallerla AV, Funnell JL, Ezzo AR, Song CL, et al. Clonal expansion of cytotoxic CD8+ T cells in lecanemab-associated ARIA. medRxiv. 2025. doi:10.1101/2025.09.17.25335728.
BibTeX
@article{johnson2025-0f059906,
author = {Johnson, L. A. and Saito, K. and Pallerla, A. V. and Funnell, J. L. and Ezzo, A. R. and Song, C. L. and Harrison, D. A. and Norton, N. J. and others},
title = {{Clonal expansion of cytotoxic CD8+ T cells in lecanemab-associated ARIA}},
journal = {medRxiv},
year = {2025},
doi = {10.1101/2025.09.17.25335728},
url = {https://doi.org/10.1101/2025.09.17.25335728}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Single-cell RNA sequencing, CITE-seq, V(D)J clonotyping, and metabolomic/lipidomic profiling revealed a coordinated reprogramming of the CD8 + compartment in ARIA+ patients.
- Together, these findings establish a peripheral immune–vascular axis linking immunometabolic reprogramming, clonal cytotoxic CD8 + expansion, and altered monocyte signaling to ARIA, with implications for biomarker development and risk mitigation during anti-amyloid therapy.
- By integrating single-cell, clonotype, and metabolomic profiling, we show that ARIA is associated with glycolysis-driven expansion of cytotoxic CD8 TEM/TEMRA subsets that engage monocyte and endothelial signaling axes.
- These findings identify a peripheral immune program that may inform biomarker development and therapeutic strategies to mitigate ARIA risk.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 19 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 12 of the 62 points we could judge it on, which is 19 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 12 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 12 of the 62 points we could judge it on is 19 out of 100. |
| Total | 19 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “cd8”
2 studies in the library carry the topic tag “cd8”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.